RxDoctor Payments Data

Giselle Ann Racho, MD

Hospitalist · Melbourne, FLNPI 1780940692

Payments from drug & device makers

$760in general payments, 2019–2025

Across 13 payments — averaging $58.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$154
  • E.r. Squibb & Sons, L.L.C.$138
  • Alkermes, Inc.$125
  • Melinta Therapeutics, LLC$122
  • AbbVie$90
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$83
  • plus $48 from 2 others

What the payments were for

  • Food & beverage$760100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$760 in reported general payments places this provider in the 75th percentile of 1,570 hospitalist providers in Florida.

See all hospitalist providers in Florida

Medicare billing

Part B allowed, 2024
$129,880
Medicare patients
507
Services billed
1,281

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban11$6,539
Cefdinir48$559
Pantoprazole Sodium19$387
Atorvastatin Calcium20$290
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav17$220
Metoprolol Succinate12$188
Donepezil Hcl12$188
Levothyroxine Sodium13$146
Losartan Potassium11$61
Metoprolol Tartrate14$45
Furosemide14$42
Amlodipine Besylate11$34
Prednisone25$33

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$6,53911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,570 hospitalist providers in Florida.

Other hospitalist in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →